Lindbrook Capital, LLC Seagen Inc. Transaction History

Lindbrook Capital, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 25, 2023	BUY	$191.51 - $216.16 $7,660 - $8,646	40 Added 20.41%	236 $50,000
Q1 2023 Apr 26, 2023	BUY	$127.59 - $203.08 $11,100 - $17,667	87 Added 79.82%	196 $39,000
Q4 2022 Jan 24, 2023	BUY	$117.37 - $139.17 $6,455 - $7,654	55 Added 101.85%	109 $0
Q3 2022 Nov 10, 2022	SELL	$135.27 - $180.11 $1,487 - $1,981	-11 Reduced 16.92%	54 $7,000
Q2 2022 Aug 01, 2022	BUY	$108.81 - $179.33 $3,481 - $5,738	32 Added 96.97%	65 $12,000
Q1 2022 Apr 21, 2022	SELL	$119.61 - $157.85 $119 - $157	-1 Reduced 2.94%	33 $5,000
Q4 2021 Jan 18, 2022	BUY	$142.57 - $190.86 $855 - $1,145	6 Added 21.43%	34 $5,000
Q3 2021 Nov 05, 2021	SELL	$142.45 - $169.82 $1,282 - $1,528	-9 Reduced 24.32%	28 $5,000
Q2 2021 Jul 27, 2021	SELL	$135.08 - $161.1 $17,830 - $21,265	-132 Reduced 78.11%	37 $6,000
Q1 2021 Apr 28, 2021	BUY	$137.51 - $190.8 $16,088 - $22,323	117 Added 225.0%	169 $23,000
Q4 2020 Jan 27, 2021	BUY	$164.63 - $211.93 $2,140 - $2,755	13 Added 33.33%	52 $9,000
Q3 2020 Nov 03, 2020	BUY	$145.95 - $195.69 $5,692 - $7,631	39 New	39 $8,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.